US Bancorp DE Raises Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

US Bancorp DE lifted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 7.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,344 shares of the company’s stock after acquiring an additional 357 shares during the period. US Bancorp DE’s holdings in Vaxcyte were worth $202,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Wells Fargo & Company MN boosted its stake in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company’s stock worth $5,916,000 after buying an additional 25,257 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after buying an additional 9,416 shares during the period. Parallel Advisors LLC boosted its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after purchasing an additional 1,071 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Vaxcyte by 12.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company’s stock valued at $4,509,000 after purchasing an additional 6,121 shares during the period. Finally, Barclays PLC raised its stake in Vaxcyte by 19.1% in the fourth quarter. Barclays PLC now owns 254,885 shares of the company’s stock valued at $20,865,000 after buying an additional 40,932 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $32.70 on Friday. The company’s 50-day simple moving average is $34.03 and its 200-day simple moving average is $46.66. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The stock has a market capitalization of $4.25 billion, a price-to-earnings ratio of -7.96 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the business posted ($1.10) EPS. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an “overweight” rating on the stock. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and an average price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.